Loading clinical trials...
Loading clinical trials...
The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 months for 2 years. Dosage was adjusted according to side effects. Neurological assessment including the determination of the Expanded Disability Status Scale (EDSS) score and ophthalmologic evaluations were performed every 3 months and during relapses. Flow cytometric analysis, brain and spinal cord MRI was performed at baseline, 6, 12, 18, and 24 months.
Age
18 - 55 years
Sex
ALL
Healthy Volunteers
No
Department of Neurology, Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Start Date
March 1, 2009
Primary Completion Date
December 1, 2014
Completion Date
December 1, 2015
Last Updated
December 27, 2013
50
ESTIMATED participants
Mitoxantrone
DRUG
Lead Sponsor
Xuanwu Hospital, Beijing
NCT07410039
NCT05966467
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06620809